A recent phase 3 clinical trial compared lorlatinib with first generation ALK inhibitor crizotinib in 296 patients with advanced ALK-positive NSCLC who had received no previous systemic treatment for metastatic disease. The gene discussed is ALK; the disease is non-small cell lung carcinoma.